IPFsym® is a mechanistic, mathematical model for QSP of idiopathic pulmonary fibrosis (IPF) that can be used to predict efficacy for potential treatments. IPF is a fatal lung disease characterized by a progressive loss of lung function that often afflicts elderly patients, dramatically increasing mortality risk. There is a substantial effort within the pharmaceutical industry to develop effective treatments for IPF patients, and we believe predictions from IPFsym will make the clinical development process more efficient! The upcoming webinar will show the validation and use of the model and software.
Topics to be covered:
- IPFsym includes the inter-patient variability in the primary pathophysiologic mechanisms (i.e, AEC cell death, inflammation, myofibroblasts, fibrosis) to generate an IPF SimPops™
- the response to the current standards of care, nintedanib, and pirfenidone
- the underlying equations can be viewed and modified by users, allowing for the simulation of new treatment modalities
- combinations of new treatments along with standards of care that can be simulated
IPFsym can be applied to support compound development at multiple locations in the pipeline, including optimizing clinical trial protocols, evaluating dosing paradigms, animal to FIH translation, and target evaluation. Be sure to join us and learn about this exciting new tool in the fight to help IPF patients!
By Scott Q Siler